An European-focused venture capital firm with partners based in Europe and USA has a current fund which is actively investing in Spain, Portugal, the UK, and Ireland. The firm is expanding into the Baltics and raising a new €100 M fund. The firm looks for companies mainly in Europe and works closely with the team to expand the business into new markets. The firm invests in Series A & B financings as a with investments ranging from €3-8 M over the life of the company. The firm is actively looking for investment opportunities and plans to make around 12 investments with the new fund over the next 4 years. The firm will only invest in private companies.

The firm is an opportunistic investor and will consider medical devices, diagnostics, and healthcare IT companies. The firm is most interested in diagnostics and healthcare IT companies as well as data- analytics and IoT companies. Previous investments include a pharmacogenetic test company and a drug delivery technology platform, clinical trial analytics and others. The firm is very opportunistic in terms of subsectors and indications. For therapeutics, the firm will only consider products that are in phase 2 stage or later. In terms of digital health, the firm has interests in consumer-facing platforms and analytics areas, such as big data-driven technologies on complex medical research.

The firm looks for management teams with highly relevant experience and strong industry knowledge is a must. The firm looks for management teams that are willing to work alongside a hands-on investor, and the firm always looks to take a board seat. The firm is open to both leading and co-investing. The firm prefers companies to be backed by strong IP protection and must have already raised seed capital.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An early stage fund with a China-based parent investment firm built its own science park near Shanghai to help companies expand successfully into the China market. The firm invests in 3 to 5 deals a year at seed stage. The fund has particular success in fostering joint development initiatives between U.S. and China-based companies. The firm invests in companies based in the U.S., China, or Europe.

The fund invests in early-stage therapeutics, medical devices, diagnostics, and healthcare IT. The firm is particularly interested in early-stage therapeutic companies, and their second priority would be diagnostics. The firm has expertise in the oncology field, and the firm is open to looking at orphan diseases. In addition, the firm is also open to lab equipment and drug development enabling technology.

The fund supports companies who have an international business model with desires to expand into the US, China, and/or Europe.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A leading venture capital investment firm provides capital and strategic support to early stage life science companies with revolutionary technologies, as well as growth stage healthcare companies with strong market presence. Located in both USA and China, the firm is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successful companies in both USA and China.

The firm continues to capitalize on a historic opportunity in the rapid growth of China’s healthcare industry as well as breakthroughs in life science research worldwide. With over $440 million in capital under management and support from some of the most prestigious LPs in the world, the firm is poised to deliver superior returns to their investors and create value for their entrepreneur partners.

The investment size generally ranges from $5 million to $20 million over the life of an investment. The firm seeks to make 3-5 allocations in the next year and focuses on companies that are based in the USA and China.

The firm is currently looking for new investment opportunities in biotechnology R&D, therapeutics & diagnostics, pharmaceuticals, medical devices and healthcare IT spaces. The firm is very opportunistic in terms of subsectors and indications. The firm is interested in in-licensing products or technologies for development from companies outside of China, such as USA-based companies. The firm also seeks to invest in orphan drugs. Prior investments have included medical device companies, diagnostics companies, CRO and distributors. The firm will consider companies in all stages, depending on the opportunity.

The firm seeks to invest in both private and public companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in Canada with an additional USA-based office is making investments out of its vintage 2017, fourth fund and is exclusively focused on advanced materials within four verticals including energy, electronics, health and sustainability. The firm typically makes initial investments in the $1-5M range and up to $10M over the life of the investment (more or less may be initially invested depending on the deal). The firm prefers to lead deals but will also participate in a syndicate as a co-investor. With strategic LP relationships in Asia, Europe and the Middle East, the firm is open to companies globally and looks to make 3-4 new investments per year.

The firm’s primary investment thesis is technology driven, breakthrough IP. Within healthcare, the firm is interested in medical devices and diagnostics whose underlying value is in the material as well as advanced materials with antibacterial properties and the like. The firm has a particular interest in 3D printing and genomics/proteomics R&D applications. The firm does not make investments in pharmaceuticals/therapeutics of any kind. Past investments have included a manufacturer of semiconductor radiation detectors enabling a new generation of detection and imaging equipment, a company developing environmentally-benign insecticides derived from compounds found in spider venom and a company developing functional surfaces with anti-microbial and anti-fouling properties.

The firm prefers to work with experienced management teams, but is open to working with less experienced entrepreneurs or incomplete management teams given the firm can add value through corporate strategy and operational experience to help accelerate development. The firm prefers to invest in revenue-generating companies but is open to evaluating pre-revenue companies as well. The firm seeks a board seat along with investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com